Evidence map›Paper›PMID 38892712›Full record

ReviewNutrients2024

Carrageenan in the Diet: Friend or Foe for Inflammatory Bowel Disease?

Nina Kimilu, Katarzyna Gładyś-Cieszyńska, Magdalena Pieszko, Dorota Mańkowska-Wierzbicka, Marcin Folwarski

Abstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nina KimiluStudents' Scientific Circle of Clinical Nutrition, Medical University of Gdansk, 80-211 Gdansk, Poland.
Katarzyna Gładyś-CieszyńskaDepartment of Clinical Nutrition and Dietetics, Medical University of Gdansk, 80-210 Gdansk, Poland.
Magdalena PieszkoDepartment of Clinical Nutrition and Dietetics, Medical University of Gdansk, 80-210 Gdansk, Poland.ORCID 0000-0002-0909-9233
Dorota Mańkowska-WierzbickaDepartment of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
Marcin FolwarskiDepartment of Clinical Nutrition and Dietetics, Medical University of Gdansk, 80-210 Gdansk, Poland.ORCID 0000-0002-7301-1689

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the exact pathogenesis of IBD remains unclear, genetic, environmental and nutritional factors as well as the composition of the gut microbiome play crucial roles. Food additives, which are increasingly consumed in the Western diet, are being investigated for their potential effects on IBD. These additives can affect gut health by altering the composition of the microbiota, immune responses, and intestinal permeability, contributing to autoimmune diseases and inflammation. Despite the growing number of studies on food additives and IBD, the specific effects of carrageenan have not yet been sufficiently researched. This review addresses this gap by critically analyzing recent studies on the effects of carrageenan on the gut microbiota, intestinal permeability, and inflammatory processes. We searched the MEDLINE and SCOPUS databases using the following terms: carrageenan, carrageenan and inflammatory bowel disease, carrageenan and cancer, food additives and microbiome, food additives and intestinal permeability, and food additives and autoimmune diseases. In animal studies, degraded carrageenan has been shown to trigger intestinal ulceration and inflammation, highlighting its potential risk for exacerbating IBD. It can affect the gut microbiota, reduce bacterial diversity, and increase intestinal permeability, contributing to "leaky gut" syndrome. Some studies suggest that carrageenan may inhibit the growth of cancer cells by influencing the progression of the cell cycle, but the anti-cancer effect is still unclear. Carrageenan may also increase glucose intolerance and insulin resistance. Further research is needed to determine whether carrageenan should be excluded from the diet of individuals with IBD.

Indexed as

CarrageenanDietGastrointestinal MicrobiomeInflammatory Bowel DiseasesAnimalsFood AdditivesHumansPermeabilityCarrageenanFood Additivescarrageenanfood additiveshealthinflammationinflammatory bowel diseasemicrobiome

Identifiers

PMID38892712
PMCPMC11174395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.